Literature DB >> 138208

Immunological monitoring of long-surviving renal transplant recipients.

J Thomas, F Thomas, G Mendez-Picon, H Lee.   

Abstract

In this study a variety of cell-mediated immunity responses were performed in long-term (2 to 12 year) human leukocyte antigen-A (HLA) nonidentical renal transplant patients. All patients showed mixed lymphocyte culture (MLC) stimulation against donor, indicating a lack of tolerance. Of successful long-term transplant patients, 73 percent showed high serum levels of MLC-blocking activity. A consistent association of successful long-term transplantation and a specific defect in recipient ability to generate cytotoxic cells against donor was seen at the 8 to 12 year level. A close association of lymphocyte-dependent activity (LDA) and clinical chronic rejection was found, and LDA could be identified prior to the onset of clinical chronic rejection in most cases. Four patients had a positive LDA assay prior to transplant and all four went on to develop chronic rejection. Recipients taking immunosuppressive drugs within 24 hours of testing had a deficient capability to generate cytotoxic effector cells against indifferent individuals. These findings demonstrate a consistent association of in vitro cell-mediated immunity parameters and in vivo transplant function and may represent a valuable immunological monitoring system for long-term recipient follow-up.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 138208

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  9 in total

1.  Serial evaluation of immune profiles of simultaneous bone marrow and whole organ transplant recipients.

Authors:  A Zeevi; M Pavlick; S Lombardozzi; R Banas; A S Rao; P Fontes; A J Demetris; R Shapiro; M Jordan; F Dodson
Journal:  Transplant Proc       Date:  1995-02       Impact factor: 1.066

Review 2.  Operational tolerance in kidney transplantation and associated biomarkers.

Authors:  A Massart; L Ghisdal; M Abramowicz; D Abramowicz
Journal:  Clin Exp Immunol       Date:  2017-05-29       Impact factor: 4.330

3.  Impact of donor MHC class I or class II antigen deficiency on first- and second-set rejection of mouse heart or liver allografts.

Authors:  S Qian; F Fu; Y Li; L Lu; A S Rao; T E Starzl; A W Thomson; J J Fung
Journal:  Immunology       Date:  1996-05       Impact factor: 7.397

4.  Immune status of recipients following bone marrow-augmented solid organ transplantation.

Authors:  A Zeevi; M Pavlick; S Lombardozzi; R Banas; O Pappo; A S Rao; P Fontes; J Demetris; R Shapiro; F Dodson
Journal:  Transplantation       Date:  1995-02-27       Impact factor: 4.939

5.  Weaning of immunosuppression in long-term liver transplant recipients.

Authors:  H C Ramos; J Reyes; K Abu-Elmagd; A Zeevi; N Reinsmoen; A Tzakis; A J Demetris; J J Fung; B Flynn; J McMichael
Journal:  Transplantation       Date:  1995-01-27       Impact factor: 4.939

6.  Murine liver allograft transplantation: tolerance and donor cell chimerism.

Authors:  S Qian; A J Demetris; N Murase; A S Rao; J J Fung; T E Starzl
Journal:  Hepatology       Date:  1994-04       Impact factor: 17.425

7.  Presensitization by skin grafting from major histocompatibility complex class I or major histocompatibility complex class II deficient mice identifies class I antigens as inducers of allosensitization.

Authors:  S Qian; F Fu; Y Li; L Gao; L Lu; H Noyola; A S Rao; A W Thomson; J J Fung
Journal:  Immunology       Date:  1995-05       Impact factor: 7.397

8.  Chimerism and donor-specific nonreactivity 27 to 29 years after kidney allotransplantation.

Authors:  T E Starzl; A J Demetris; M Trucco; A Zeevi; H Ramos; P Terasaki; W A Rudert; M Kocova; C Ricordi; S Ildstad
Journal:  Transplantation       Date:  1993-06       Impact factor: 4.939

9.  Correlation of donor antigen-specific hyporeactivity with allogeneic microchimerism in kidney and lung recipients.

Authors:  N L Reinsmoen; C McSherry; B Chavers; M I Hertz; A J Matas
Journal:  Pediatr Nephrol       Date:  1995       Impact factor: 3.714

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.